- Home
- NNY vs SGMT Comparison
NNY vs SGMT Comparison
Compare NNY & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNY
- SGMT
- Stock Information
- Founded
- NNY 1987
- SGMT 2006
- Country
- NNY United States
- SGMT United States
- Employees
- NNY N/A
- SGMT N/A
- Industry
- NNY Investment Managers
- SGMT
- Sector
- NNY Finance
- SGMT
- Exchange
- NNY Nasdaq
- SGMT Nasdaq
- Market Cap
- NNY 157.9M
- SGMT 159.0M
- IPO Year
- NNY N/A
- SGMT 2023
- Fundamental
- Price
- NNY $8.16
- SGMT $4.39
- Analyst Decision
- NNY
- SGMT Buy
- Analyst Count
- NNY 0
- SGMT 6
- Target Price
- NNY N/A
- SGMT $23.00
- AVG Volume (30 Days)
- NNY 50.9K
- SGMT 1.2M
- Earning Date
- NNY 01-01-0001
- SGMT 11-13-2024
- Dividend Yield
- NNY 4.04%
- SGMT N/A
- EPS Growth
- NNY N/A
- SGMT N/A
- EPS
- NNY N/A
- SGMT N/A
- Revenue
- NNY N/A
- SGMT N/A
- Revenue This Year
- NNY N/A
- SGMT N/A
- Revenue Next Year
- NNY N/A
- SGMT N/A
- P/E Ratio
- NNY N/A
- SGMT N/A
- Revenue Growth
- NNY N/A
- SGMT N/A
- 52 Week Low
- NNY $7.58
- SGMT $2.39
- 52 Week High
- NNY $8.87
- SGMT $20.71
- Technical
- Relative Strength Index (RSI)
- NNY 52.11
- SGMT 44.30
- Support Level
- NNY $8.05
- SGMT $4.06
- Resistance Level
- NNY $8.13
- SGMT $7.38
- Average True Range (ATR)
- NNY 0.07
- SGMT 0.63
- MACD
- NNY 0.02
- SGMT -0.11
- Stochastic Oscillator
- NNY 66.67
- SGMT 9.94
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from both regular federal and New York state income taxes, by investing primarily in a portfolio of municipal obligations issued by state and local government authorities within the state of New York or certain U.S. territories.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).